An Arizona couple, Dr Stephen Johnston and his wife Kristina, have pledged $7.1 million towards research into inherited retinal diseases, following their son Luke's diagnosis with Bardet-Biedl syndrome in 2020. The family's initial search for a treatment has evolved into a broader mission to fund research, supporting both gene-specific and gene-agnostic approaches to combat inherited blindness.
The Johnstons founded the nonprofit organization A Race Against Blindness in 2023 after being told that little could be done for their son's condition. In response, they decided to help fund research into potential treatments, turning their personal struggle into a wider effort to support children and families affected by inherited retinal diseases.
The latest commitment of $1 million, announced in November 2026, was made in partnership with the Foundation Fighting Blindness. The funding will be divided between two research initiatives: $700,000 to the Gund Vision Fund and $300,000 for research led by Dr Jin Woo Kim at the Korea Advanced Institute of Science and Technology (KAIST).
The grant aims to refine an antibody designed to block a protein called PROX1 and its delivery, with further studies required before it can be considered for human trials. The research focuses on encouraging the retina's own cells to regenerate, offering potential direction for future treatments. A previous $1 million commitment in June 2026 also supported research led by Dr Thomas Mendel at The Ohio State University.
Prior to expanding its focus, A Race Against Blindness had concentrated on finding a therapy for Luke's specific genetic condition. The organization provided $5.1 million to support the development of AXV-101, an experimental gene therapy designed for retinal degeneration associated with mutations in the BBS1 gene. The therapy has now entered a first-in-human clinical trial, assessing its preliminary safety and tolerability in children with BBS1-related retinal degeneration.
The family's commitment to research offers new hope for individuals affected by inherited retinal diseases, with the ultimate goal of restoring vision and improving quality of life for those impacted.